Filing Analysis
📝 Material Agreement
Filed May 26, 2026
⚪ LOW
Neuphoria Therapeutics received an AUD 1.416M revenue distribution payment from its participation in the former CTx CRC, triggered by Pfizer initiating a Phase III trial for the licensed KAT6 program. The company is eligible for approximately 4.65% of future milestones from a total potential pool of USD 460M.
🚩 Red Flags
- The company is a passive party and cannot guarantee if or when future milestones will be achieved or paid.
📋 Key Facts
- Received AUD 1,416,026 on May 21, 2026, from CTx CRC participation.
- Payment was triggered by the initiation of dosing in the first Phase III Clinical Trial of the KAT6 program in ER+/HER2- metastatic breast cancer by licensee Pfizer Inc.
- Neuphoria is eligible to receive approximately 4.65% of future milestone payments from the program, with the total combined value for all 17 partners estimated at USD 460 million.
- Total cumulative distributions received by the company from the CRC trusts since 2016 amount to AUD 3,522,413.68.
- Neuphoria Therapeutics Inc. was formerly known as Bionomics Ltd.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.